Immune control of oncogene selection in preneoplastic colon
Immune control of oncogene selection in preneoplastic colon
批准号:
10740144
负责人:
Haris Mirza
金额:
$18.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-14 至 2028-08-31
关键词:
AffectAgeAnatomyArchitectureBayesian MethodBlocking AntibodiesCancer EtiologyCancerousCell ProliferationCellsCellular MorphologyCessation of lifeClone CellsColonColon CarcinomaColonic NeoplasmsColonoscopyDataDevelopmentDiagnosisEpitheliumEvolutionGoalsHistologicHumanImmuneImmune systemImmunologic SurveillanceImmunopreventionIn VitroIncidenceIndividualInfiltrationInterleukin-10LabelLesionMajor Histocompatibility ComplexMalignant NeoplasmsMentorsMolecularMorphologyMucous MembraneMusMutateMutationOncogenesOncogenicOrganoidsPathway interactionsPatientsPhysiciansPrevention strategyPrevention therapyProgram DevelopmentProliferatingRegulationRegulatory T-LymphocyteReporterResearchResearch PersonnelRoleScientistShapesSignal TransductionSupporting CellT cell infiltrationT-Cell DepletionT-LymphocyteTechniquesTestingTherapeuticTimeTraining ProgramsTubeWomanWorkbasecancer initiationcareer developmentcell typecolon cancer preventioncytokineepithelial stem cellexperimental studyinterleukin-10 receptorintestinal cryptmouse modelmutantneoplasticpremalignantpreventsegregationstem cell biologystem cellstranscriptomicstreatment strategytumortumor immunologytumor microenvironmenttumor-immune system interactions
中文摘要
结肠癌是通过上皮干细胞中致癌突变的逐步积累而发生的
细胞这些突变的干细胞在健康的结肠中通过阳性选择繁殖多年,
转化成癌症在这个建议中,我的目标是解开一个免疫监视机制,
阻止健康结肠中突变干细胞的选择。BRAFV 600 E结肠癌
突变涉及近端结肠,不成比例地影响65岁以上的女性
年基于这些癌症独特的解剖学和人口学分布,我建议
BRAFV600E突变的干细胞在近端结肠中具有很强的选择性优势。
调节性T细胞是结肠干细胞微环境的一部分,
BRAFV600E突变的癌症。因此,我假设调节性T细胞识别并
抑制健康结肠中BRAFV600E突变干细胞的选择。为了验证这一
假设,我已经开发了几种遗传诱导谱系追踪小鼠,
在单个结肠干细胞中诱导BRAFV 600 E突变。用这些老鼠,我将解剖
调节性T细胞用于监视
BRAFV600E突变的干细胞。确定调节性T细胞在癌基因中的作用
选择将导致针对结肠癌的免疫预防疗法的发展。的
建议还包括在具有专业知识的导师指导下的严格培训计划
在肿瘤免疫学、干细胞生物学和癌症演变方面。完成建议
这些活动将帮助我实现成为一名独立的物理学家和科学家的目标,
研究针对结肠癌的免疫预防策略。
英文摘要
Colon cancers develop by stepwise accumulation of oncogenic mutations in epithelial stem
cells. These mutated stem cells multiply by positive selection in healthy colon for years before
transforming into cancers. In this proposal I aim to unravel an immune surveillance mechanism
that prevents selection of mutated stem cells in healthy colon. Colon cancers with BRAFV600E
mutation involve the proximal colon and disproportionately affect women above the age of 65
years. Based on the unique anatomic and demographic distribution of these cancers, I propose
that BRAFV600E mutated stem cells have a strong selective advantage in the proximal colon.
Regulatory T cells are part of the colonic stem cell microenvironment and, also heavily infiltrate
BRAFV600E mutated cancers. Thus, I hypothesize that the regulatory T cells recognize and
suppress the selection of BRAFV600E mutated stem cells in the healthy colon. To test this
hypothesis, I have developed several genetically inducible lineage tracing mice that specifically
induce BRAFV600E mutation in a single colonic stem cell. Using these mice, I will dissect the
molecular mechanisms employed by regulatory T cells to perform surveillance against
BRAFV600E mutated stem cells. Establishing the role of regulatory T cells in oncogene
selection will lead to development of immune-prevention therapies against colon cancers. The
proposal also includes a rigorous training program under the guidance of mentors with expertise
in tumor immunology, stem cell biology and cancer evolution. Completion of the proposed
activities will help me realize my goal of becoming an independent physician-scientist,
investigating immune preventive strategies against colon cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: